Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:MDWDNASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21824,951 shs554,788 shsMDWDMediWound$19.09-1.7%$19.36$13.49▼$24.00$206.36M0.3890,693 shs55,739 shsMNMDMind Medicine (MindMed)$7.05-0.6%$6.77$4.70▼$10.44$532.63M2.521.35 million shs1.27 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%0.00%+188.10%MDWDMediWound0.00%-6.51%-6.28%+16.05%+41.83%MNMDMind Medicine (MindMed)0.00%-1.67%-3.42%+1.88%-4.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.6677 of 5 stars3.50.00.04.00.60.01.9MDWDMediWound1.586 of 5 stars3.51.00.00.00.00.80.6MNMDMind Medicine (MindMed)1.43 of 5 stars3.60.00.00.01.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideMDWDMediWound 3.00Buy$31.8066.58% UpsideMNMDMind Medicine (MindMed) 3.27Buy$25.50261.70% UpsideCurrent Analyst Ratings BreakdownLatest MDWD, CDXC, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025MDWDMediWoundOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$34.005/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/2/2025MDWDMediWoundAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00MDWDMediWound$20.22M10.21N/AN/A$2.89 per share6.61MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/AMDWDMediWound-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)Latest MDWD, CDXC, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35MDWDMediWoundN/A2.151.99MNMDMind Medicine (MindMed)0.107.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%MDWDMediWound46.83%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%MDWDMediWound9.20%MNMDMind Medicine (MindMed)2.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionableMNMDMind Medicine (MindMed)4075.55 million73.85 millionOptionableMDWD, CDXC, and MNMD HeadlinesRecent News About These CompaniesMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.3% - Here's WhyJune 18, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.8% - Here's WhyJune 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for MNMD FY2026 EarningsJune 10, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by BrokeragesJune 9, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Two Sigma Investments LPJune 5, 2025 | marketbeat.comMillennium Management LLC Increases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 5, 2025 | marketbeat.comWhy Mind Medicine Gave Investors a Powerful Buzz in MayJune 4, 2025 | msn.comBank of America Corp DE Reduces Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 4, 2025 | marketbeat.comWall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to TradeJune 2, 2025 | zacks.comMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerMay 27, 2025 | finance.yahoo.comHC Wainwright Has Pessimistic Outlook of MNMD Q3 EarningsMay 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for MNMD Q1 Earnings?May 25, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of MNMD FY2025 EarningsMay 25, 2025 | marketbeat.comNorthern Trust Corp Has $4.77 Million Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 24, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Acquired by AWM Investment Company Inc.May 23, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsMay 19, 2025 | businesswire.comDoes Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?May 13, 2025 | zacks.comWhy Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%May 12, 2025 | aaii.comEarnings call transcript: MindMed Q1 2025 results show mixed signalsMay 10, 2025 | uk.investing.comMind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comMind Medicine (MindMed) Inc. 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDWD, CDXC, and MNMD Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.MediWound NASDAQ:MDWD$19.09 -0.34 (-1.75%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$19.14 +0.05 (+0.24%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Mind Medicine (MindMed) NASDAQ:MNMD$7.05 -0.04 (-0.56%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.95 -0.10 (-1.39%) As of 09:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
